NTLA Stock Recent News
NTLA LATEST HEADLINES
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.
Cathie Wood bought shares of Shopify, Intellia, and Adaptive Biotechnologies on Tuesday. Shopify has surrendered 26% of its value over the past two weeks since posting disappointing guidance.
From a technical perspective, Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick, as it just reached a key level of support. NTLA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates.
Wood added to her positions in Roblox, Accolade, and Intellia Therapeutics on Thursday. Roblox had a decent first quarter, but weak guidance sent the shares more than 20% lower on Thursday.
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago.
In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $23.60, marking a +1.42% move from the previous day.